Vol. 5 No. 9 (2025)
Reimbursement Reviews

Blinatumomab (Blincyto)

Published September 3, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses blinatumomab (Blincyto), 28 mcg/day for patients weighing 45 kg and more and 15 mcg/m2 per day for patients weighing less than 45 kg (up to a maximum of 28 mcg/day), lyophilized powder for solution, IV infusion by infusion pump.
  • Indication: For the treatment of patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy.